Table 1.
Patient baseline characteristics
| Dialysis patients (n = 302) | Kidney transplant recipients (n = 1034) | P-value | |
|---|---|---|---|
| Age (years) | 73.07 ± 14.33 | 58.71 ± 13.15 | < 0.0001 |
| Gender (male) | 197 (65) | 668 (65) | 0.81 |
| Ethnicity | 0.01 | ||
| Caucasian | 271 (91) | 965 (93) | |
| Hispanic | 10 (3) | 34 (3) | |
| Asian | 4 (1) | 15 (2) | |
| African American | 4 (1) | 7 (1) | |
| Arabic | 13 (4) | 12 (1) | |
| BMI (kg/m2) | 25.10 ± 5.56 | 26.00 ± 4.80 | 0.007 |
| Diabetes (yes) | 127 (42) | 233 (23) | < 0.001 |
| Smoking habit (yes) | 84 (28) | 187 (18) | < 0.001 |
| Hypertension (yes) | 204 (67) | 814 (79) | < 0.001 |
| Coronary Heart Disease (yes) | 77 (26) | 126 (12) | < 0.001 |
| Dialysis modality | – | ||
| Haemodiafiltration | 286 (94) | – | |
| Haemodialysis | 16 (5) | – | |
| Transplant modality | – | ||
| KTA | – | 911 (88) | |
| SPK | – | 88 (9) | |
| Other | – | 35 (3) | |
| Dialysis vintage (months) | 35 [19–69] | 20 [6–43] | 0.23 |
| Transplant vintage (months) | 0.5 [0–96] | 106 [47–193] | < 0.001 |
| Previous KT (any) | 13 (16) | 219 (21) | 0.32 |
| Induction IS | |||
| No | – | 205 (19) | |
| Basiliximab | – | 361 (34) | |
| Thymoglobulin | – | 492 (47) | |
| Maintenance IS | |||
| TAC + MPA | – | 624 (59) | |
| TAC + mTORi | – | 255 (24) | |
| Other | – | 179 (17) | |
| Pre-vaccine COVID-19 (yes) | 27 (9) | 81 (8) | 0.55 |
| COVID-19 vaccine | < 0.001 | ||
| mRNA-1273 | 194 (64) | 1,027 (99) | |
| BNT162b2 | 108 (36) | 7 (1) |
Data are mean ± SD, median [IQR] or n (%), unless otherwise specified. BMI, Body Mass Index; KTA, Kidney Transplantation Alone; SPK, Simultaneous Pancreas-Kidney; KT, Kidney Transplantation; IS, Immunosuppression; TAC, Tacrolimus; MPA, Mycophenolate; mTORi, mTOR inhibitors; COVID-19, Coronavirus Disease 2019